Novel translational approaches to tackle the challenges of hard-to-treat cancers from early diagnosis to therapy

Apply now
Proposals must be centred on one or more of the hard-to-treat-cancers (HTTC) subtypes characterized by very poor prognosis (5-year survival rate<25%) and for which survival has not improved significantly over the last decades, namely glioblastoma, oesophageal, pancreatic, gallbladder, liver, and lung/pleural cancers.

Proposals must be centred on one or more of the hard-to-treat-cancers (HTTC) subtypes characterized by very poor prognosis (5-year survival rate<25%) and for which survival has not improved significantly over the last decades, namely glioblastoma, oesophageal, pancreatic, gallbladder, liver, and lung/pleural cancers.

Current difficulties include the inadequacy of standard diagnostic tools or established early detection methods in the general population, but also the inefficacy of available treatment options, due to intrinsic resistance and/or ineffective drug delivery. In the context of translational cancer research, this call for proposals comprises three specific aims. Proposals will have to cover at least one of the undermentioned aims or sub-aims.

Aim 1: Identification/validation of novel early diagnostic approaches.
Aim 2: Identification/validation of novel therapeutic approaches.
Aim 3: Development of novel drug delivery strategies.

Read the full proposal and apply on the TRANSCAN website.

Messages at time of print 28 May 2022, 17:56 CEST

No global messages displayed at time of print.